Yixintang Pharmaceutical Group Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Yixintang Pharmaceutical Group Co., Ltd. carries a market capitalization of 6.12B, placing it among publicly traded companies globally. Its enterprise value stands at 9.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.12B |
| Enterprise Value | 9.43B |
Share Statistics
Yixintang Pharmaceutical Group Co., Ltd. currently has 585.60M shares outstanding.
| Shares Outstanding | 585.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Yixintang Pharmaceutical Group Co., Ltd. trades at a trailing price-to-earnings ratio of 116.88. The price-to-sales ratio is 0.54, and the price-to-book ratio stands at 1.85.
| PE Ratio | 116.88 |
| PS Ratio | 0.54 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | 33.54 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Yixintang Pharmaceutical Group Co., Ltd. trades at an EV/EBITDA multiple of 18.37 and an EV/FCF ratio of 27.58. The EV/Sales ratio of 0.54 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.37 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.54 |
| EV / EBITDA | 18.37 |
| EV / EBIT | 18.37 |
| EV / FCF | 27.58 |
Financial Position
Yixintang Pharmaceutical Group Co., Ltd. maintains a current ratio of 1.32, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.65, indicating elevated leverage, while an interest coverage ratio of 3.66 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.32 |
| Quick Ratio | 0.46 |
| Debt / Equity | 38.65 |
| Debt / EBITDA | 5.71 |
| Interest Coverage | 3.66 |
Financial Efficiency
Yixintang Pharmaceutical Group Co., Ltd. posts a return on equity of 1.56 and a return on invested capital of 1.90.
| Return on Equity (ROE) | 1.56 |
| Return on Assets (ROA) | 0.49 |
| Return on Invested Capital (ROIC) | 1.90 |
| Return on Capital Employed (ROCE) | 1.71 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.06 |
Taxes
Over the trailing twelve months, Yixintang Pharmaceutical Group Co., Ltd. has paid 111.19M in income taxes, reflecting an effective tax rate of 59.52.
| Income Tax | 111.19M |
| Effective Tax Rate | 59.52 |
Stock Price Statistics
Yixintang Pharmaceutical Group Co., Ltd.'s stock has declined approximately -36.24161% over the past 52 weeks. The 50-day moving average sits at 11.60, while the 200-day moving average is 12.92.
| Beta (5Y) | N/A |
| 52-Week Price Change | -36.24161% |
| 50-Day Moving Average | 11.60 |
| 200-Day Moving Average | 12.92 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Yixintang Pharmaceutical Group Co., Ltd. generated 17.61B in revenue and converted that into 81.88M in net income, yielding earnings per share of 0.13. EBITDA reached 513.50M, while operating income came in at 513.50M.
| Revenue | 17.61B |
| Gross Profit | 5.70B |
| Operating Income | 513.50M |
| Pretax Income | 186.82M |
| Net Income | 81.88M |
| EBITDA | 513.50M |
| EBIT | 513.50M |
| Earnings Per Share (EPS) | 0.13 |
Balance Sheet
Yixintang Pharmaceutical Group Co., Ltd. holds 3.24B in cash and equivalents against 2.93B in total debt, resulting in a net debt position of -2.48B. Total book value stands at 5.19B, with working capital of 2.28B providing operational flexibility.
| Cash & Cash Equivalents | 3.24B |
| Total Debt | 2.93B |
| Net Debt | -2.48B |
| Equity (Book Value) | 5.19B |
| Book Value Per Share | 8.85 |
| Working Capital | 2.28B |
Cash Flow
After subtracting -285.31M in capital expenditures, free cash flow totaled -285.31M - equivalent to -0.49 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -285.31M |
| Free Cash Flow | -285.31M |
| FCF Per Share | -0.49 |
Margins
Yixintang Pharmaceutical Group Co., Ltd. operates with a gross margin of 32.36, reflecting its pricing power and cost economics. The operating margin of 2.92 and net profit margin of 0.46 provide insight into operational efficiency.
| Gross Margin | 32.36 |
| Operating Margin | 2.92 |
| Pretax Margin | 1.06 |
| Profit Margin | 0.46 |
| EBITDA Margin | 2.92 |
Dividends & Yields
The company's payout ratio of 278.43 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.33 |
| Dividend Yield | N/A |
| Payout Ratio | 278.43 |
| Shareholder Yield | 15.71 |
| FCF Yield | 2.98 |
Stock Splits
Yixintang Pharmaceutical Group Co., Ltd.'s most recent stock split took place on April 13, 2016 with a 1:2 split ratio.
| Last Split Date | 4/13/2016 |
| Split Ratio | 1:2 |
Scores
Yixintang Pharmaceutical Group Co., Ltd. posts an Altman Z-Score of 2.72, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.72 |